For the quarter ending 2025-09-30, INO has $69,385,656 in assets. $77,105,633 in debts. $36,567,420 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 36,567,420 | 24,351,377 | ||
| Short-term investments | 14,235,770 | 23,198,083 | ||
| Accounts receivable from affiliated entity | 978,590 | 840,312 | ||
| Prepaid expenses and other current assets | 3,398,534 | 4,307,377 | ||
| Total current assets | 55,180,314 | 52,697,149 | ||
| Fixed assets, net | 2,740,356 | 3,089,293 | ||
| Investments in affiliated entity | 2,495,730 | 3,085,348 | ||
| Operating lease right-of-use assets | 6,956,780 | 7,356,238 | ||
| Other assets | 2,012,476 | 2,012,476 | ||
| Total assets | 69,385,656 | 68,240,504 | ||
| Accounts payable and accrued expenses-Nonrelated Party | 15,323,520 | 15,750,691 | ||
| Accounts payable and accrued expenses-Related Party | 379,721 | 369,370 | ||
| Accrued clinical trial expenses | 955,970 | 1,510,984 | ||
| Common stock warrant liabilities | 50,384,043 | 11,420,326 | ||
| Operating lease liability | 2,738,490 | 2,656,239 | ||
| Grant funding liability from affiliated entity | 42,152 | - | ||
| Total current liabilities | 69,823,896 | 31,707,610 | ||
| Operating lease liability, net of current portion | 7,281,737 | 8,001,989 | ||
| Total liabilities | 77,105,633 | 39,709,599 | ||
| Preferred stock | 0 | 0 | ||
| Common stock | 53,572 | 36,719 | ||
| Additional paid-in capital | 1,811,803,850 | 1,802,589,299 | ||
| Accumulated deficit | -1,818,930,043 | -1,773,433,371 | ||
| Accumulated other comprehensive loss | -647,356 | -661,742 | ||
| Total inovio pharmaceuticals, inc. stockholders equity | -7,719,977 | 28,530,905 | ||
| Total liabilities and stockholders equity | 69,385,656 | 68,240,504 | ||
INOVIO PHARMACEUTICALS, INC. (INO)
INOVIO PHARMACEUTICALS, INC. (INO)